News and Press Releases
Research | CFTR Modulators | Drug Pipeline Cystic Fibrosis Foundation statement on FDA approval of TRIKAFTA, the first triple combination therapy for the most common CF mutation

This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.  

| 3 min read
About the CF Foundation | Public Policy | Drug Pipeline Statement from the Cystic Fibrosis Foundation on Senate HELP Committee’s Approval of the EXPERRT Act

Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments

| 3 min read
About the CF Foundation | Drug Pipeline | Our Research Approach Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs

New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis

| 4 min read
About the CF Foundation | Drug Pipeline | Antibiotics FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade

CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality

| 4 min read